She did her general medical training at University of Goettingen and Toronto. She has completed her specialist training to become a board certified neurologist. She obtained a higher research degree in Clinical Neurophysiology in Germany in 2003. Her thesis was about the brain excitability in patients with focal dystonia. She then worked as a postdoctoral fellow in the field of electrophysiology of movement and movement disorders. Since 2006 she has worked for John Rothwell who is a Professor for Neurophysiology at UCL.
Her research in the Unit of Functional Neurosurgery is focusing on the exploration of the mechanism of an effective deep brain stimulation by using electrophysiological and imaging techniques. Clinically she is doing pre and post surgery management of the patients. She has been published 67 times for her research works with 2093 citations.
Her research in the Unit of Functional Neurosurgery is focusing on the exploration of the mechanism of an effective deep brain stimulation by using electrophysiological and imaging techniques. Clinically she is doing pre and post surgery management of the patients.
Her research into cannabis and its effects on the neurosystem will prove valuable to produce products to help promote the medicinal benefits of cannabis.
Paul has been a long-standing proponent of Ayurveda and natural well-being. For nearly two decades, he has actively engaged in promoting Ayurvedic products and building informed perspectives around the ancient sciences of Ayurveda and Yoga. Paul’s passion for Ayurveda stems from his first-hand association with the subject – an association that dates back to his early years. In 1998, he established Herbland Limited, an Ayurvedic products enterprise first headquartered in New York, USA, and eventually in Toronto, Canada.
Over the years, Paul has built lasting relationships within the Ayurveda community, along with a worldwide network of experts, scholars, teachers and practitioners in the fields of Ayurveda, Yoga and herbal remedies. He is currently based in Toronto and continues his advocacy of natural well-being through the Ayurveda Mantra Magazine, a bi-monthly repository of articles from Ayurveda and Yoga experts that he aims to publish in multiple languages.
Paul is also one of the Founders of Ayurveda Association of Canada (AAC) a federally registered not for profit organisation. The AAC was formed to empower the Ayurveda Community by bringing the Ayurveda Community together, to create awareness about the most acient medicine system amoungst the wellness industry and get Ayurveda as one of the mainstream medicine stystem throughout the world.
Paul looks forward to introducing CBD to Ayurveda industry and to help CIRCA formulate novel products.
Dr. Rosania has been published 78 times for his work in Pharmaceutical Sciences, Drug Biocrystals, Pharmcokinetics, Formulation, Drug Targeting and Drug Delivery. He was awarded the 2018 American Association of Pharmaceutical Scientists Fellow, AAPS
The Rosania lab studies the microscopic transport properties of small drug-like molecules inside cells. Our overarching hypothesis is that a drug’s microscopic distribution within organelles is as important as its macroscopic distribution in organs in determining efficacy and toxicity. We use microscopic imaging instruments to capture the local distribution and dynamics of small molecules inside cells and analyze image data with innovative computational tools and statistical strategies, combining cheminformatics and machine vision to relate the chemical structure of small molecules to their subcellular distribution. We also develop biochemical analysis methods to study the microdistribution and cellular pharmacokinetics of small drug-like molecules. Lastly, we build mathematical models to simulate drug transport and distribution in single cells and higher order cellular organizations, based on biophysical principles governing molecular transport phenomena at the cellular level.
We envision a day when drugs are designed, optimized, and approved based on their site of action, much as drugs today are designed, optimized, and approved based on their molecular mechanism of action.
His research team brings a lot of research and resources to Circa to advance our goals to become a leader in the medical side of the industry.